Diversified Trust’s Enanta Pharmaceuticals ENTA Stock Holding History

Diversified Trust’s Portfolio ENTA Stock Details ENTA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-16,900	Closed	-$159K	–	868
2023 Q4	$159K	Buy	+16,900	New	+$157K	0.01%	804

Other funds holding ENTA

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

KAM

Krensavage Asset Management New York $256M AUM 69.63% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Diversified Trust's ENTA Position: Q1 2024 in Review

Diversified Trust sold out of Enanta Pharmaceuticals (ENTA) in Q1 2024, closing a stake of 16,900 shares — an estimated $159K sold.

Diversified Trust first reported a position in ENTA in Q4 2023 and held it in 1 quarter. The position peaked at $159K in Q4 2023. 107 funds tracked by Wall St. Rank hold ENTA as of Q1 2024.

Diversified Trust reported no remaining Enanta Pharmaceuticals position as of Q1 2024 after selling out during the quarter.
Diversified Trust sold 16,900 Enanta Pharmaceuticals shares in Q1 2024, an estimated $159K.
Diversified Trust first reported a position in Enanta Pharmaceuticals in Q4 2023 and held it in 1 quarter.
Diversified Trust's Enanta Pharmaceuticals position peaked at $159K in Q4 2023.
107 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q1 2024.

Based on Diversified Trust's 13F filing for Q1 2024, filed 18 Apr 2024.